Latest Research And Development News

Critical Resources Limited has secured a 12-month exclusive option to evaluate advanced solid-state lithium-ion battery technology from the South Dakota School of Mines & Technology, aiming to enhance battery safety, performance, and commercial potential.

Catapult Sports Ltd has reported a robust first half of FY26, with a 19% increase in Annualized Contract Value and a 50% jump in operating profit, driven by strategic acquisitions and strong SaaS growth.

Aurora Labs has entered a strategic MOU with Ares Armaments to co-develop advanced metal components for defence, aiming to revolutionise small-arms manufacturing with additive technology.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

New Zealand Coastal Seafoods (ASX – NZS) marked a key milestone with its MV Bluefin's maiden Coral Sea fishing trip and is advancing plans for a $2 million capital raise amid strategic rebranding.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.

Spacetalk Ltd has secured an $877k R&D tax refund for FY2025, more than doubling last year’s amount, underscoring its strategic pivot to software and a 20% growth in recurring revenue.

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

First Graphene Limited has raised A$3.5 million through a share placement to accelerate the commercial adoption of its PureGRAPH graphene products and support ongoing operations.